Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
38 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Mumps - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Mumps - Pipeline Review, H2 2014', provides an overview of the Mumps's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Mumps, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mumps and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Mumps - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Mumps and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Mumps products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Mumps pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Mumps - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Mumps pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Mumps Overview 6 Therapeutics Development 7 Pipeline Products for Mumps - Overview 7 Pipeline Products for Mumps - Comparative Analysis 8 Mumps - Therapeutics under Development by Companies 9 Mumps - Therapeutics under Investigation by Universities/Institutes 10 Mumps - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Mumps - Products under Development by Companies 14 Mumps - Products under Investigation by Universities/Institutes 15 Mumps - Companies Involved in Therapeutics Development 16 Beijing Tiantan Biological Products Co., Ltd. 16 China National Pharmaceutical Group Corporation 17 GlaxoSmithKline plc 18 Prometheon Pharma, LLC 19 Zydus Cadila Healthcare Limited 20 Mumps - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Combination Products 22 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 measles + mumps + rubella + varicella vaccine - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 measles + mumps + rubella + varicella vaccine - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 measles + mumps + rubella vaccine - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 measles + mumps + rubella vaccine - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 measles + mumps + rubella vaccine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 mumps vaccine - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Mumps - Recent Pipeline Updates 33 Mumps - Dormant Projects 34 Mumps - Product Development Milestones 35 Featured News & Press Releases 35 Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus 35 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Number of Products under Development for Mumps, H2 2014 7 Number of Products under Development for Mumps - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Late Stage Development, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Mumps - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2014 16 Mumps - Pipeline by China National Pharmaceutical Group Corporation, H2 2014 17 Mumps - Pipeline by GlaxoSmithKline plc, H2 2014 18 Mumps - Pipeline by Prometheon Pharma, LLC, H2 2014 19 Mumps - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 20 Assessment by Monotherapy Products, H2 2014 21 Assessment by Combination Products, H2 2014 22 Number of Products by Stage and Route of Administration, H2 2014 24 Number of Products by Stage and Molecule Type, H2 2014 26 Mumps Therapeutics - Recent Pipeline Updates, H2 2014 33 Mumps - Dormant Projects, H2 2014 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.